ArticleBMC musculoskeletal disorders2026
A modified surgical strategy for proximal femur benign tumors: a retrospective analysis of 100 patients.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe proximal femur is a common site for benign bone tumors and tumor-like lesions, which often lead to pathological fractures and structural instability. However, these lesions are highly heterogeneous, and in some cases, conventional internal fixation cannot adequately meet surgical requirements. Currently, there is no consensus on the optimal surgical strategy for such conditions. This study aimed to evaluate whether a lesion-categorization-based surgical approach could improve postoperative functional recovery and to explore the feasibility of joint-preserving treatment in cases with severe structural destruction.
methodsA retrospective analysis was conducted on 100 patients who underwent surgical treatment for benign tumors of the proximal femur between 2020 and 2024. Tumors were classified based on lesion location, size, extent of femoral head destruction, and the presence of deformities. Surgical strategies were selected according to this classification. Postoperative function was assessed using the Musculoskeletal Tumor Society (MSTS) scoring system. A Bayesian linear regression model and intergroup comparisons were employed to evaluate the impact of the classification on clinical outcomes.
resultIn this study, a modified surgical strategy was proposed to categorize benign proximal femoral bone lesions into five types, with corresponding surgical strategies developed for each type. Type 1 and 2 lesions were characterized by mild cortical involvement and relatively stable structures suitable for curettage, bone grafting, with or without internal fixation. Type 3-5 showed progressive bone loss and deformity requiring limited internal fixation combined with external fixation (LIFEF), corrective osteotomy, or endoprosthetic replacement (EPR). The cohort had a mean age of 37.3 years (range 17–69) and a mean follow-up duration of 25.0 ± 14.9 months (range 3–54 months). The MSTS-93 score at the final follow-up was 26.1 ± 1.0. Bayesian analysis revealed statistically credible differences in postoperative MSTS scores among the three groups: Type 1, Type 2, and "Other types" (Types 3-5). The overall complication rate was 5%, including mild limping, transient pain, and mild avascular necrosis.
conclusionsThe lesion-categorization-based surgical strategy provides a practical and effective framework for managing benign tumors of the proximal femur. This approach optimizes postoperative functional recovery, supports joint preservation where feasible, and may serve as a reference for standardized surgical decision-making. LEVEL OF EVIDENCE: IV; Retrospective observational study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.